Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
Todd W. Miller(Dartmouth College), Carlos L. Arteaga(The University of Texas Southwestern Medical Center)
Cited by 463
Related Papers
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
|Cancer Discovery|2021|241
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer
|Nature Genetics|2015|166
Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated Tumor
|JAMA Oncology|2020|106
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.
|Journal of Clinical Oncology|2019|82